On February 1, 2023, OncoHost, a precision diagnostics company centered on predictive biomarker development for improved patient care, announced the official launch of its PROphet® non-small cell lung cancer (NSCLC) Test in the United States. OncoHost’s first test, PROphet® NSCLC, guides first-line treatment decisions for advanced unresectable NSCLC patients. The PROphet® NSCLC Test provides clinicians with actionable clinical insights into optimal first-line therapeutic choices, and a better understanding of their patients’ personalized cancer dynamics. Requiring just one pre-treatment blood test, PROphet® scans approximately 7,000 proteins in a patient's blood plasma and delivers a report that predicts the patient’s clinical benefit from anti-PD-1/PD-L1 immunotherapy-based treatment plans versus clinical benefit from immunotherapy plus chemotherapy.
Login Or Register To Read Full Story